Abstract
In Sweden, ICIs have been reimbursed since 2015 for locally advanced/metastatic NSCLC. ICI monotherapy has been used as second-line (2L) treatment for squamous carcinoma (SQ) since December 2015, for non-squamous carcinoma (NSQ) since June 2016, and as first-line (1L) treatment for high programmed death-ligand-1 (PD-L1) expressors (≥50%) since March 2017. This study from the SCAN LEAF project, part of the I-O Optimise initiative, assessed the early use of ICIs for the real-world management of advanced/metastatic NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
